![Dépression résistante : SPRAVATO, nouvel antidépresseur à base d'eskétamine en solution pour pulvérisation nasale Dépression résistante : SPRAVATO, nouvel antidépresseur à base d'eskétamine en solution pour pulvérisation nasale](http://vidalactus.vidal.fr/gestionnaire/_images/mediatheque/Capturedecran2020-10-08a15.16.40.png)
Dépression résistante : SPRAVATO, nouvel antidépresseur à base d'eskétamine en solution pour pulvérisation nasale
![These highlights do not include all the information needed to use SPRAVATO ® safely and effectively. See full prescribing information for SPRAVATO ®. SPRAVATO ® (esketamine) nasal spray, CIII Initial U.S. Approval: 1970 (ketamine) These highlights do not include all the information needed to use SPRAVATO ® safely and effectively. See full prescribing information for SPRAVATO ®. SPRAVATO ® (esketamine) nasal spray, CIII Initial U.S. Approval: 1970 (ketamine)](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=spravato-01.jpg&id=708098)
These highlights do not include all the information needed to use SPRAVATO ® safely and effectively. See full prescribing information for SPRAVATO ®. SPRAVATO ® (esketamine) nasal spray, CIII Initial U.S. Approval: 1970 (ketamine)
![Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior](https://mma.prnewswire.com/media/1222835/SPRAVATO_Logo.jpg?p=facebook)